倍搏集團(08331.HK)擬股份「十合一」後「一供一」
倍搏集團(08331.HK)公佈,擬進行股份合併,將每10股每股面值0.01元之已發行及未發行現有股份合併爲1股每股面值0.1元之合併股份。
董事會建議待(其中包括)股份合併生效後,按於記錄日期每持有1股合併股份獲發1股供股股份之基準,以認購價每股供股股份0.35元進行供股,透過向合資格股東發行7,955.72萬股供股股份,籌約2,780萬元。認購價爲每股供股股份0.35元,較前收市價每股0.055元計算之理論收市價每股合併股份0.55元折讓將36.4%。(el/k) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.